Swiss Re AG

Swiss Re reported H1 2026 net income of USD 2.8 billion, versus a full-year target of USD 4.5 billion, and a 23% return on equity. P&C Reinsurance reported an insurance service result of USD 1.8 billion and a combined ratio of 76.7% in H1; current-service experience variance was around USD 350 million, supported by nat cat losses coming in USD 676 million below expectations, and past-service experience was around USD 350 million, reflecting reserve releases across short-tail lines of more than USD 1 billion. Corporate Solutions reported a combined ratio of 86.1% and insurance service result of USD 578 million. Life & Health Re net income was just over USD 1 billion, insurance service result was USD 1.2 billion, CSM release was USD 758 million, ROI was 4.0%, and recurring income was USD 2 billion. On guidance, management reiterated confidence in P&C Re staying below its 85% full-year combined ratio target, said Life & Health Re remains on track to deliver its USD 1.7 billion 2026 net income target, and raised the operating cost reduction target to USD 500 million by 2028, with the lower run-rate fully reflected in full-year 2029.

The CEO framed the half-year as proof that Swiss Re’s diversified model and cycle management approach are working, highlighting underwriting discipline, portfolio quality, and capital management. He said the company is preserving quality, improving efficiency, and expanding in cycle-decorrelated lines and attractive growth markets, while still defending margins in a competitive environment. His tone was confident but measured, emphasizing resilience rather than aggressive growth.

The CFO focused on the quality of earnings and reserve strength. He said P&C Re’s USD 1.8 billion insurance service result was driven by favorable current and past service experience, including over USD 1 billion of short-tail reserve releases, while the company added around USD 500 million to IBNR reserves for long-tail lines in Q2 and earlier reserves for Middle East conflict-related inflation risk. He also cited a group SST ratio of 264%, up 14 points since 1 January 2026, partly helped by subordinated debt issuance, and noted progress on the USD 1.5 billion share buyback, with about 60% executed by the end of July.

Analysts pressed on whether the USD 1 billion of short-tail reserve releases were structural and whether long-tail additions signaled deterioration; management said the releases reflect both low nat cat activity and prudent reserving, and that the long-tail additions were about prudence, not worsening trends. Questions also focused on the decline in new business CSM and whether it implied lower 2027 earnings; management said the reduction mainly reflected business mix and higher loss picks, not broad pricing weakness, and declined to give 2027 guidance yet. On Life & Health Re, management said new business CSM remains lumpy because of transaction timing, but expects the second half to return to a more normal run rate.